Have any questions? 706-721-6582 or cts@augusta.edu
- MEI-011: A Two-Stage, Open-Label Followed by Placebo Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents
Clinical Trial
MEI-011: A Two-Stage, Open-Label Followed by Placebo Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents
The purpose of this study is to learn how the investigational drug, called Pracinostat, works, including how safe it is when given with the approved drug, Azacitidine, in subjects diagnosed with advanced myelodysplastic syndrome (MDS).
Eligibility Criteria
- - Male or female 18 years of age or older - Diagnosis of Myelodysplastic Syndrome (MDS) - Treatment with approved drug, Azacitidine, must be indicated
RESEARCH. INNOVATION. DISCOVERY.